IP Library Granted Patent US 10,921,332
Granted Patent B2
US 10,921,332 · App. 15/646,303 · Granted Feb 16, 2021

Collagen IV binding assay for the detection of collagen VII

Inventor: Sheila G. Magil (Arlington, MA)
Assignee: PHOENIX TISSUE REPAIR, INC.
G01N33/94G01N33/6887G01N2333/78
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,921,332
App. No.
15/646,303
Granted
Feb 16, 2021
Kind
B2
Abstract

The present disclosure features a method of detecting and/or quantifying collagen VII or a fragment thereof in a sample, the method including contacting the sample with collagen IV or a fragment thereof which binds to collagen VII; and contacting the sample with an anti-collagen VII antibody, wherein the anti-collagen VII antibody binds to the NC2 domain of collagen VII; detecting binding of the anti-collagen VII antibody to thereby detect and/or quantify an amount of collagen VII or the fragment thereof in the sample. A method of evaluating or processing a collagen VII preparation is also provided.

Claims (13)

1. A method for evaluating or processing a collagen VII preparation comprising determining the presence or amount of collagen VII in the preparation, the method comprising:

(a) contacting the preparation or a sample of the preparation with collagen IV, or a fragment thereof;

(b) contacting the sample contacted with collagen IV, or a fragment thereof, with an anti-collagen VII antibody that binds to collagen VII in a collagen VII-collagen IV complex;

(c) measuring the level of collagen VII bound to collagen IV by detecting and quantifying anti-collagen VII antibody bound to collagen VII in the collagen VII-collagen IV complexes;

(d) detecting and/or quantifying the amount of collagen VII in the sample, thereby determining the presence or amount of collagen VII in the preparation; and

(e) comparing the value determined for the presence or amount of collagen VII in the sample with a reference value, thereby evaluating or processing the collagen VII preparation;

wherein the collagen VII preparation is a collagen VII substance preparation or a collagen VII drug product preparation.

2. The method of claim 1 , wherein the comparison includes determining if the value determined for the presence or amount of collagen VII in the sample has a preselected relationship with the reference value.

3. The method of claim 2 , wherein the method further comprises determining if the value determined for the presence or amount of collagen VII in the sample is equal to or greater than, or is less than or equal to, or falls within a range of, either inclusive or exclusive of one or both endpoints, the reference value.

4. The method of claim 3 , wherein the indication of the preselected relationship is memorialized in a computer readable record.

5. The method of claim 2 , wherein the preselected relationship is met, and the sample is further processed into drug product or formulated.

6. The method of claim 2 , wherein the preselected relationship is met, and the sample is subjected to purification.

7. The method of claim 1 further comprising determining one or more of the properties of collagen VII in the test sample.

Assignments (7)
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL Recorded Mar 5, 2025
From: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
To: BRIDGEBIO PHARMA, INC.; QED THERAPEUTICS, INC.; EIDOS THERAPEUTICS, INC.; ML BIO SOLUTIONS INC.; CALCILYTIX THERAPEUTICS INC.; ADRENAS THERAPEUTICS INC.; PHOENIX TISSUE REPAIR, INC.; NAVIRE PHARMA, INC.; VENTHERA, INC.; MOLECULAR SKIN THERAPEUTICS, INC.; CANTERO THERAPEUTICS, INC.; COA THERAPEUTICS, INC.; PORTAL THERAPEUTICS, INC.; BRIDGEBIO GENE THERAPY RESEARCH, INC.; FERRO THERAPEUTICS, INC.
Reel/Frame 070551/0095 →
SECURITY INTEREST Recorded Jan 19, 2024
From: BRIDGEBIO PHARMA, INC.; QED THERAPEUTICS, INC.; EIDOS THERAPEUTICS, INC.; THERAS, INC.; ML BIO SOLUTIONS INC.; CALCILYTIX THERAPEUTICS INC.; ADRENAS THERAPEUTICS INC.; PHOENIX TISSUE REPAIR, INC.; NAVIRE PHARMA, INC.; VENTHERA, INC.; MOLECULAR SKIN THERAPEUTICS, INC.; CANTERO THERAPEUTICS, INC.; COA THERAPEUTICS, INC.; PORTAL THERAPEUTICS, INC.; BRIDGEBIO GENE THERAPY RESEARCH, INC.; FERRO THERAPEUTICS, INC.; SUB21, INC.
To: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 066355/0126 →
RELEASE OF SECURITY INTEREST Recorded Jan 18, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS SUCCESSOR TO U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: BRIDGEBIO PHARMA, INC.; ORIGIN BIOSCIENCES, INC.; EIDOS THERAPEUTICS, INC.; QED THERAPEUTICS, INC.; ADRENAS THERAPEUTICS, INC.; PHOENIX TISSUE REPAIR, INC.
Reel/Frame 066167/0462 →
SECURITY INTEREST Recorded Jan 17, 2024
From: CALCILYTIX THERAPEUTICS INC.; ADRENAS THERAPEUTICS INC.; PHOENIX TISSUE REPAIR, INC.; NAVIRE PHARMA, INC.; VENTHERA, INC.; MOLECULAR SKIN THERAPEUTICS, INC.; CANTERO THERAPEUTICS, INC.; COA THERAPEUTICS, INC.; PORTAL THERAPEUTICS, INC.; BRIDGEBIO GENE THERAPY RESEARCH, INC.; FERRO THERAPEUTICS, INC.; SUB21, INC.
To: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 066342/0154 →
SECURITY INTEREST Recorded Nov 17, 2021
From: BRIDGEBIO PHARMA, INC.; ORIGIN BIOSCIENCES, INC.; EIDOS THERAPEUTICS, INC.; QED THERAPEUTICS, INC.; ADRENAS THERAPEUTICS, INC.; PHOENIX TISSUE REPAIR, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 058144/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2017
From: MAGIL, SHEILA G.
To: LOTUS TISSUE REPAIR INC.
Reel/Frame 043577/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2017
From: SHIRE HUMAN GENETIC THERAPIES, INC.; LOTUS TISSUE REPAIR, INC.
To: PHOENIX TISSUE REPAIR, INC.
Reel/Frame 043572/0252 →
Continuity (3)
Continuation 14440958
Provisional Application 61723372 · Nov 7, 2012
Related Publication 20180011118A1 · Jan 11, 2018